Traditional tumor biomarkers are proteins that have been shed in the bloodstream and have been critical in identifying and treating cancer. We sought to survey proteins relevant to oncology in colon and prostate tumors; in order to identify potential proteins of interest for cancer research. Four colon and three prostate tumors were homogenized and 115 proteins were analyzed from the Oncology MAP 2.0. Each tumor had 2 fractions homogenized to look at heterogeneity of the protein with the tumor. In all of the samples measured 102 of the 115 protein showed levels above the LLOQ. Five proteins (PSP94, Tenascin-X, lipocalin-1, Tie-1 and BAFF) were 100 fold higher in prostate tumors compared to colon tumors (P<0.001). PSP94 has been shown to be a prostate cancer marker in serum; however, none of the other markers have been shown to be markers of prostate tumors. Eight proteins (PECAM-1, CA 72-4, Eotaxin-2, HGF-R, CA 15-3, TATI, CEACAM6 and CEA) were greater than 10 fold higher in colon tumors compared to prostate tumors (P<0.001). Although oncology MAP 2.0 was developed for serum biomarkers, it may provide a valuable tool for examining proteins biomarkers in tumors.

Citation Format: Laurie L. Stephen, Marc Damour, Josh Kemp, Karri L. Ballard, Ralph L. McDade, James P. Mapes. Analysis of protein biomakers in prostate and colorectal tumor lysates. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2500. doi:10.1158/1538-7445.AM2013-2500